Oncaspar, a combination treatment for acute lymphocytic leukemia (ALL), which has been supplied by developer Servier, is forming a stable prescription maintenance environment. According to related industries, it passed the Drug Committee (DC) of the Big 5 general hospitals, including Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.

Since May, the supplier has been changed at the rare drug center, but the prescription code has been quickly secured. Oncaspar obtained permission for import items from the MFDS in February last year as a combination therapy with other anti-tumor drugs when treating Acute Lymphoblastic Leukemia (ALL).

This drug maximiz